Originality picture / new capital signs up for reporter Wang Yuanzheng
104 net profit appears negative growth, indebted rate exceeds the asset of 60 enterprises 50%
(on receive D01 edition)
Earn money most enterprise -- Heng Rui medicine
Ability of research and development is outstanding " market prise one elder brother "
Appear on the market in 293 in medical biology enterprise, vest in of constant luck medicine appears on the market the net gain of company shareholder is 4.066 billion yuan, grow 26.39% compared to the same period, it is the company with top specified number of profit of the net in 293 enterprises.
Constant luck medicine advocate business Wu involves drug research and development, production and sale, main product is covered fight anaesthesia of tumor medicine, operation kind wait for numerous domain with agent of medicine, special infusion, radiography, cardiovascular drug. In medicine board piece, constant luck medicine is called " market prise one elder brother " , " A become known horse " , be medical domain " classy unripe " .
Ability of research and development of constant luck medicine is outstanding, sulfur earthed up the department that be not case to well balanced inject fluid is obtained successfully 2018 batch appear on the market, pyrrole is replaced the Buddhist nun is clinical II period obtains revolutionary curative effect, obtain conditional approval to appear on the market, bead sheet fights card Rayleigh (lymphatic tumour gets used to card) obtain first try to review a qualification and already finished technical careful evaluate work to make. Inside report period, company accumulative total invests capital of research and development 2.67 billion yuan, grow 51.81% compared to the same period, investment of research and development occupies sales revenue proportion to achieve 15.33% .
Constant luck medicine expresses, implementation of each economic norms grew steadily 2018, on one hand the results of achievement of profit from innovation, pull a movement to use to arriving since growth of company outstanding achievement. Inside report period, the company has 56 innovation medicine to be in clinical development. In innovation development respect formed medicine basically already to have innovation drug every year application is clinical, every 2-3 year the benign development state that innovation medicine appears on the market. Additional, company product structure is optimized further, as company product structural adjustment, the company blame that is a delegate with agent of operation anaesthesia, radiography and characteristic infusion fights tumor drug product to be inside respective cure domain escalate market, continue to maintain stability to rise situation.
Constant luck medicine expresses, will continue to advance the internationalization of innovation of research and development and preparation product steadily next, in the meantime, also exert oneself at product structure optimize promotion, ensure company outstanding achievement can grow continuously.
The enterprise with maximum loss -- ST coronal blessing
Gigantic deficient outstanding achievement has turned 2.7 billion yuan this year
Controlled partner is violated compasses assure external, external loan violate compasses item influence, 2018, coronal blessing company realizes battalion to receive forteen billion two hundred and ninety-three million yuan, vest in appears on the market profit of company shareholder net is - 2.712 billion yuan, glide compared to the same period 1059.99% .
Actually, coronal blessing is not to be in deficit condition all the time. Its release 3 quarterly reports showed 2018, inside report period, the company realizes business income ten billion seven hundred and thirty-eight million yuan, grow 71.78% compared to the same period, net profit 393 million yuan, soar compared to the same period 176.05% . Enter four quarters, the company controls a partner (Lin is familial) because its pilot company or financing of affiliated enterprise oneself are tight, reach through the company control share company fulfilling company interior to examine and approve decision-making process situation to fall, happen to be reached with the company accuse share company name to open commercial accept bill of exchange, assure external, with company and subsidiary name external loan violate compasses item, amount exceeds 2.366 billion yuan, initiated many dispute and lawsuit. To on October 14, 2018, the company accuses a partner to did not raise money to be able to solve the capital of debt effectively, company stock was executed since reopen after a cessation of business on October 16, 2018 oneself other venture caution, stock abbreviation by " coronal blessing share " change is " ST coronal blessing " , company stock trades sun rises drop a limitation for 5% .
ST coronal blessing is in said in annals 2018, the company is inside report period answer actively to accuse 5 days of name of share company Shanghai to open commercial accept bill of exchange to accusing a partner to be reached through the company, assure external, external loan violate compasses item, it is normal to made sure production is managed. ST coronal blessing releases the newspaper showed first quarter 2019, inside report period, the company realizes battalion to receive 3.41 billion yuan, grow 6.53% compared to the same period, vest in appears on the market profit of company shareholder net is 158 million yuan, decrease compared to the same period 39.83% . In the meantime, the company predicts vest in appears on the market first half of the year this year the net gain of company shareholder is 550 million yuan - 680 million yuan between, grow 67.29%-106.84% compared to the same period.
The company with indebted top rate -- 1000 yam machine
Market prise shrink exceeds 9 to become or appear on the market time-out
2018 implementation battalion accepts 1000 yam plane 201 million yuan, glide compared to the same period 34.78% ; Vest in appears on the market the net gain of company shareholder is - 2.466 billion yuan, glide compared to the same period 660.89% .
"Big health " the concept stars a 1000 yam machine since appearing on the market in May 2011 oneself, share price ever highest violent wind rises reach 109 yuan of April 27, 2014 / , market prise ever achieved 30 billion yuan for a time. The 1000 yam machine that announces good news all the way, explode in impawn of investigation of deep-set 2018 put on record, equity however storehouse, outstanding achievement is gigantic wait for eddy fortunately, face the risk that retreat city. Before stopping a card on April 26 this year, company market prise only 1.377 billion yuan, shrink exceeds 9 to become.
On January 13, 2018, 1000 yam machine releases announcement to say, the company stock of hold of place of hill of iron of the biggest partner and Liu Xianghua of consistent action person, Deng is frozen by judicatory, the reason is 30 million yuan loan assumes two factitious brushstroke to assure jointly jointly responsibility be caused by.
1000 yam machine says, because the incident such as debt crisis, lawsuit brings about circulating fund inadequacy, at present order of company pharmacy machinery is shown considerably downtrend, be like the problem of company insoluble circulating fund, dissolve the risk element such as debenture Wu crisis, production is managed will produce major change. If the creditor of the company is right the hope that the company did not develop is scant, may apply for a company to go bankrupt to the court.
Since this year, the risk clew announcement that 1000 yam machine had issued 15 to may be suspended appearing on the market continuously. Began stock of 1000 yam machine to stop a card on April 24 from this year, hand in greatly place general trades 15 times in a few days to make the decision that whether suspends appearing on the market after stopping a card.
Most the business that be willing to part with or use popularizes -- the pace grows pharmacy
Day all 20 million do promotion to occupy battalion to close 6 into
Pace long pharmacy is current deep-set " case of fraud of American recruit students " in disturbance, although statement of president Zhao Tao says, the daughter studies abroad long pharmacy of capital and pace has nothing to do, do not make any impacts to firm financial standing, but doubt still is continueing, all the time since the tall cost of sales that gets dispute fully is occupied than be being alluded again.
In 292 enterprises, the cost of sales of pace long pharmacy is ranked the 3rd, be as high as 8.036 billion yuan, occupy battalion to close than amounting to 58.81% . The book of IPO raise capital by floating shares that long pharmacy of pace of basis of reporter of new capital newspaper releases before this and the calendar year annual report that after appearing on the market, issue comb discovery, of pace long pharmacy " the market and academic promotion " occupy battalion to accept scale all the time very big, and present year after year to increase a current, and charge of research and development occupies battalion to close than not tall however.
2018, the company realizes battalion to receive thirteen billion five hundred and sixty-five million yuan, net profit is 1.888 billion yuan, cost of sales is as high as 8.036 billion yuan however, cost of sales occupies battalion to close than achieving 58.81% . Of cost of sales 93.15% for " the market and academic promotion reach advisory cost " , this means the market that costs on average 2018 everyday and academic promotion expenses to be as high as 20.5 million yuan.
Compare with photograph of tall cost of sales, the pace grows pharmacy to although also be growth of year after year,be in on investment of research and development, but amount is shown slightly however " persnickety " . Since appearing on the market, data shows, came 2016 2018, the investment of research and development that pace long pharmacy invests is 459 million yuan respectively, 553 million yuan mix 576 million yuan, investment of research and development occupies battalion to receive scale to be respectively 3.72% , 3.99% , 4.22% . What research and development invested amount 2018 is announce to appear on the market in 281 in medical biology enterprise, the pace grows pharmacy to rank the 141st.
Most the enterprise of research and development of be willing to part with or use -- industry of Bei Da drug
Investment of research and development occupies battalion to close than be as high as 48.2%
Industry of Bei Da drug landed A in November 2016, be called " anticarcinogen the first " , it is one puts in what the doctor establishs 's charge by the sea, with own intellectual property innovation medicaments research and development are core, collect medicine research and development, production, sale the national level at an organic whole is new and high technical company. 2011, the country of company own research and development the new drug letter that dust gram obtains former state to feed medical inspect bureau to issue for the Buddhist nun mixes 1.1 kinds of new drug to produce batch of article and begin to appear on the market sale, become the main source of company income and profit. Up to on December 31, 2018, dust gram replaces the Buddhist nun already benefit and patient of nearly 200 thousand terminal lung cancer, accumulative total sells more than 5.75 billion yuan. 2018, dust gram is sold for the Buddhist nun continue to the limit of one's capacity, annual sells a number to break through 1 million first, rise compared to the same period 30.45% .
2018, shellfish amounts to medical industry to realize battalion to receive 1.224 billion yuan, grow 19.27% compared to the same period; Vest in appears on the market profit of company shareholder net is 167 million yuan, glide compared to the same period 35.27% . To the reason that outstanding achievement glides, shellfish amounts to medical industry explanation, basically be charge of research and development and overhead expenses increase be caused by.
Regard medicine of an innovation sex as the enterprise, the investment that shellfish amounts to medical industry to go up in research and development fits be willing to part with or use. 2018, the investment of research and development of the company achieves 590 million yuan, occupy battalion to close than be as high as 48.20% , relatively go up growth of year of the corresponding period 55.01% . Inside report period, projects of many research and development gained milepost headway, besides refer Sha of hydrochloric acid favour to replace the Buddhist nun outside NDA, still refer 5 IND, pass the effort on job of new drug research and development, cop of the company's current research and development is abounded further, laid a foundation to enrich prospective product line to hit.
